Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) Insider Sells 1,977 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) insider David Shook sold 1,977 shares of the business’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $12.64, for a total transaction of $24,989.28. Following the transaction, the insider owned 20,923 shares in the company, valued at $264,466.72. This trade represents a 8.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lyell Immunopharma Stock Performance

LYEL stock traded up $0.50 during mid-day trading on Thursday, reaching $13.72. 142,506 shares of the stock traded hands, compared to its average volume of 97,895. Lyell Immunopharma, Inc. has a one year low of $8.46 and a one year high of $45.00. The stock has a market capitalization of $320.09 million, a PE ratio of -0.99 and a beta of -0.09. The business has a 50-day moving average price of $19.45 and a two-hundred day moving average price of $23.36.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.10). The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. On average, equities analysts expect that Lyell Immunopharma, Inc. will post -7.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on LYEL shares. Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Citizens Jmp initiated coverage on shares of Lyell Immunopharma in a report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Lyell Immunopharma in a report on Tuesday. Finally, Robert W. Baird set a $49.00 price objective on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lyell Immunopharma currently has an average rating of “Moderate Buy” and an average target price of $43.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Foresite Capital Management V LLC grew its position in Lyell Immunopharma by 17.3% in the 3rd quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock valued at $7,748,000 after acquiring an additional 70,426 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. lifted its stake in Lyell Immunopharma by 33.3% in the third quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company’s stock valued at $891,000 after buying an additional 13,722 shares during the last quarter. Two Sigma Investments LP lifted its stake in Lyell Immunopharma by 107.0% in the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after buying an additional 10,768 shares during the last quarter. ExodusPoint Capital Management LP purchased a new stake in Lyell Immunopharma in the fourth quarter valued at approximately $262,000. Finally, Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma in the second quarter valued at approximately $258,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.